Environmental, Social and Governance (ESG) considerations have moved from the periphery to the core of legal and strategic decision-making across the life sciences industry. For pharma, biotech and medical device companies, all operating complex global supply chains, ESG is no longer a voluntary aspiration. It is quickly becoming a binding legal requirement.

With the German Act on Corporate Due Diligence Obligations in Supply Chains (Lieferkettensorgfaltspflichtengesetz, LkSG) already in force and the EU Corporate Sustainability Due Diligence Directive (CSDDD) on the horizon, companies face intensified expectations. Germany is now preparing national legislation to implement the CSDDD, further tightening due diligence obligations.

Why it matters

Life sciences supply chains are global, complex and exposed to regulatory scrutiny. Contractual clauses are now a key tool for implementing ESG obligations:

• Codes of Conduct referencing internal policies or international frameworks
• Audit & reporting rights enabling transparency and continuous monitoring
• Flow-down obligations ensuring subcontractors and lower-tier suppliers meet the same ESG standards
• Remediation clauses that prioritise corrective action before termination
• Termination rights for ESG breaches when issues remain unresolved

These mechanisms help companies implement due diligence obligations rather than relying on broad policy commitments.

Enforceability concerns

Under German law, many ESG clauses qualify as General Terms and Conditions (GTC). This means they must be proportionate, transparent and reasonable to be enforceable. Overly broad rights, especially termination rights, may be invalid.

At the same time, German and EU due diligence laws require companies to take preventive measures with direct suppliers. Contracts must therefore reflect regulatory obligations to avoid compliance gaps.

The opportunity

Well-structured ESG clauses help companies demonstrate due diligence, reduce liability, improve investor perception and meet procurement criteria. They also position life sciences companies for upcoming EU-level obligations.

Life sciences businesses should therefore review and strengthen their contractual ESG frameworks now. Strong clauses are becoming a competitive advantage and in fact, a legal necessity.